The Quantellect read.As of Nov 19, 2026, 9 active firms cover Fulcrum Therapeutics Inc: 1 rate it Buy or better, 5 sit at Neutral, and 3 rate it Sell or worse, a neutral consensus. The target range is very wide, $3.00 to $24.00 (about 8.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.67 sits 133% above the current $3.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-0.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Neutral
Strong Buy00%
Buy111%
Neutral556%
Sell333%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.67
+132.7% upside
Average target across 9 active firms as of Nov 19, 2026 vs $3.73 current
Highest Target$24.00
Average Target$8.67
Lowest Target$3.00
Detailed analyst forecasts for FULC
Showing 1–8 of 8 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 1 of 9 active firms rate FULC a Buy (5 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FULC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.36 – $-0.36 · 1 analysts · +44% YoY
Next period, 1 analysts expect Fulcrum Therapeutics Inc to earn $-0.36 a share (range $-0.36 – $-0.36), versus $-0.25 a year earlier. Full-year consensus is $-0.84, growing to $-0.66 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Fulcrum Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FULC.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Neutral
$3.00-19.5% to target
Overall win rate
45%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$4.00+7.4% to target
Overall win rate
49%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Sell
No targeton FULC
Overall win rate
48%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$24.00+544.3% to target
Overall win rate
38%
+ Follow
#5
Joseph Schwartz
Leerink Partners · Rank #242
Neutral
$4.00+7.4% to target
Overall win rate
36%
+ Follow
FULC stock forecast FAQ
What is FULC's average 12-month price target?+
The 9 active firms with a live target average $8.67 for Fulcrum Therapeutics Inc over the next 12 months, ranging from a $24.00 high to a $3.00 low, as of Nov 19, 2026.
Is FULC stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 9 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 5 rate it Neutral, and 3 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FULC?+
The Street-high target is $24.00 (Cantor Fitzgerald), and the Street-low is $3.00 (Stifel). The average of all 9 active-firm targets is $8.67.
How many active Wall Street firms cover FULC?+
9 active firms have a recognized rating on Fulcrum Therapeutics Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FULC?+
Among analysts who currently cover FULC, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Neutral with a $3.00 target.
What is Fulcrum Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.36 – $-0.36) across 1 analysts. Full-year EPS is projected at $-0.84, rising to $-0.66 the following year.
How much revenue is Fulcrum Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading FULC lately?+
As of Nov 19, 2026, 1 of 9 active firms rate FULC a Buy (5 Neutral, 3 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FULC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.